{"id":546944,"date":"2010-04-29T10:49:17","date_gmt":"2010-04-29T14:49:17","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=76575"},"modified":"2010-04-29T10:49:17","modified_gmt":"2010-04-29T14:49:17","slug":"celladon-enjoys-early-success-with-gene-therapy-trial-fda-gives-digirad-green-light-for-a-nuclear-camera-aragon-pharmaceuticals-gets-22m-more-san-diego-biotech-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/546944","title":{"rendered":"Celladon Enjoys Early Success With Gene Therapy Trial, FDA Gives Digirad Green Light for a Nuclear Camera, Aragon Pharmaceuticals Gets $22M & More San Diego Biotech News"},"content":{"rendered":"\n
Roundup<\/a>, Life Sciences<\/a>, funding<\/a><\/div>\n

\t\tBruce V. Bigelow wrote:<\/strong><\/p>\n

We saw a healthy mix of life sciences news over the past week, with a generous serving of device news, some venture funding, a dash of clinical trial results, and voila! Enjoy!<\/p>\n

—San Diego’s Celladon<\/strong> said an experimental gene therapy treatment met its primary goal of showing the treatment was more effective than a placebo<\/a> in a trial that enrolled 39 heart patients. The experiment tested a single-shot infusion of Mydicar, Celladon’s gene therapy drug.<\/p>\n

—San Diego’s <\/strong>Aragon Pharmaceuticals<\/strong> said it raised $22 million in venture funding to advance its lead drug treatment for prostate cancer into an initial clinical trial<\/a>. The startup is testing a new approach to treating cancers by targeting certain hormones.<\/p>\n

—The slicing and dicing of venture capital data from the first three months of 2010 continued this week, with a new MoneyTree<\/strong> report saying life sciences is holding its position as the largest single industry getting venture capital funding nationwide. The report, “Holding the Lead,” says VC firms invested $1.3 billion in 160 deals nationwide—representing 28 percent of all dollars invested and 23 percent of the deals.<\/a> The report was prepared by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters.<\/p>\n

—San Diego’s Digirad<\/strong> (NASDAQ: DRAD<\/a>) said the FDA gave the Poway, CA, company approval to market Ergo, a nuclear imaging camera system for hospitals that’s smaller and more portable<\/a> than existing hospital systems.<\/p>\n

—Luke profiled San Diego-based NuVasive<\/strong> (NASDAQ: NUVA<\/a>), which has developed a new approach for repairing damaged or aging vertebrae. NuVasive’s technology enables surgeons to go into the body through a patient’s side, rather that through the front or back, giving doctors easier access to the spine.<\/a><\/p>\n

—The Flax Council of Canada is investing about $5.5 million through a partnership with San Diego’s Cibus Global<\/strong> to develop a crop strain of flax that is resistant to glyphosate, the active ingredient in the widely used weed killer Roundup<\/a>. Cibus says it intends to develop a strain that’s acceptable to Europeans opposed to genetically modified crops.<\/p>\n


<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Life Sciences, funding Bruce V. Bigelow wrote: We saw a healthy mix of life sciences news over the past week, with a generous serving of device news, some venture funding, a dash of clinical trial results, and voila! Enjoy! —San Diego’s Celladon said an experimental gene therapy treatment met its primary goal of showing […]<\/p>\n","protected":false},"author":5423,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-546944","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/546944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/5423"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=546944"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/546944\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=546944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=546944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=546944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}